99mtc-rhannexin v-128
Small moleculeexperimentalImaging agent
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2014 (NCT02328027)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 99-technetium
Oral
No
Parenteral
No
Topical
No
Also known as
- 99mtc-rhannexin v-128
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03832582 | Phase 2 | May 1, 2019 | Assistance Publique - Hôpitaux de Paris |
| NCT03232580 | Phase 2 | Sep 18, 2017 | Advanced Accelerator Applications |
| NCT02667457 | Phase 2 | Apr 1, 2016 | Advanced Accelerator Applications |
| NCT02677714 | Phase 2 | Apr 1, 2016 | Advanced Accelerator Applications |
| NCT02328027 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2014 | Advanced Accelerator Applications, University of Lausanne |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Advanced Accelerator Applications | For profit | 4 | 4 | 1 | 2014 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Lausanne | Academic/Hospital | 1 | 0 | 1 | 2014 |
3 organizations
Page 1 / 1